Lake Street analyst Eric Martinuzzi lowered the firm’s price target on Cellebrite (CLBT) to $22 from $24 and keeps a Buy rating on the shares. Slower-moving Q1 deals in Europe came through in Q2, but the U.S. federal softness persisted in Q2 and is “not expected to break loose until October,” the analyst tells investors in a post-earnings note. The federal issue will lower 2025 revenue more than originally expected, so the firm is trimming its estimates, the analyst added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLBT:
- Cellebrite Reports Strong Q2 2025 Growth and Leadership Changes
- Cellebrite DI Reports Strong Financial Growth in H1 2025
- Cellebrite price target lowered to $24 from $25 at BofA
- Positive Outlook for Cellebrite DI: Strategic Developments and Financial Discipline Justify Buy Rating
- Deere, Cisco dip after quarterly reports: Morning Buzz